Top 10 Global Leaders in Anticoagulant Drugs: Brands & Manufacturers
1 September 2025 Category: Clinical TrialHere’s what that means: traditional anticoagulants—like warfarin and LMWHs—still form the backbone of hospital and community care
Here’s what that means: traditional anticoagulants—like warfarin and LMWHs—still form the backbone of hospital and community care
Companies have realized the era of innovation and advance drug developments is around the corner. One of the key areas that is witnessing a surge is monoclonal antibodies.
Artificial intelligence (AI) has become a transformative force in the increasingly digitized healthcare environment.
2025 is not just another year, a wave of innovation is crashing through biotech and bioinformatics, reshaping every stage of clinical development.
AI is no longer a distant vision in healthcare. It’s a $13.8 billion market today—and it's projected to soar past $164 billion by 2029. That’s over 1,000% growth in just a few years.
Clinical trials are drowning in data. That's not hyperbole—it's mathematics.
Global biologics sales crossed $411 billion in 2024, with top-performing therapies treating cancer, autoimmune disorders, and rare diseases.
The design and development of orphan drugs, designed for rare diseases, are uniquely challenged as limited patient populations available for clinical trials.
Clinical trials are the foundation on which medical innovation is built beginning from the development of a new treatment or therapy.
Clinical trials are more like innovations in drug therapy and perhaps even more important if they synonymously mean life-saving.